Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell

See also
Status	Clinical Trial	Phase
Completed	`NCT00959686` - Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma	Phase 2
Active, not recruiting	`NCT04712864` - Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma	Phase 1
Recruiting	`NCT05665530` - A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies	Phase 1
Completed	`NCT01941680` - High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
Recruiting	`NCT05075460` - Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma	Phase 3
Completed	`NCT03734601` - Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation	Phase 2
Completed	`NCT02017613` - Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies	Phase 1
Enrolling by invitation	`NCT01854112` - Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma	N/A
Completed	`NCT01553786` - Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)	Phase 2
Completed	`NCT00542919` - A Study for Patients With Non-Hodgkin's Lymphomas	Phase 2
Recruiting	`NCT06131801` - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Active, not recruiting	`NCT03952078` - A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma	Phase 1
Not yet recruiting	`NCT05387226` - Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma	Phase 1
Completed	`NCT02424045` - Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma	Phase 2
Completed	`NCT01871675` - Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies	Phase 1
Terminated	`NCT00893516` - CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma	Phase 2
Completed	`NCT01902225` - Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma	Phase 1
Recruiting	`NCT02086591` - A Phase II Study of Doxycycline in Relapsed NHL	Phase 2
Recruiting	`NCT04264078` - Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies	Early Phase 1
Completed	`NCT00001582` - Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer

NCT number	NCT04331119
Study type	Interventional
Source	Washington University School of Medicine
Contact	Amanda Cashen, M.D.
Phone	314-454-8323
Email	acashen@wustl.edu
Status	Recruiting
Phase	Phase 2
Start date	July 23, 2020
Completion date	July 31, 2027

Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms